121 related articles for article (PubMed ID: 38176855)
1. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.
Liu M; Guo T; Ma Z; Du L; Hou J; Tian Y; Meng M; Chen X
Ther Drug Monit; 2024 Jun; 46(3):344-350. PubMed ID: 38176855
[TBL] [Abstract][Full Text] [Related]
2. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
3. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.
Farag S; Verheijen RB; Martijn Kerst J; Cats A; Huitema AD; Steeghs N
Clin Pharmacokinet; 2017 Mar; 56(3):287-292. PubMed ID: 27435281
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.
Zhuang W; Qiu HB; Chen XM; Yuan XH; Yang LF; Sun XW; Zhou XJ; Huang M; Wang XD; Zhou ZW
Biomed Chromatogr; 2017 Dec; 31(12):. PubMed ID: 28621487
[TBL] [Abstract][Full Text] [Related]
5. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
[TBL] [Abstract][Full Text] [Related]
6. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
[TBL] [Abstract][Full Text] [Related]
8. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
10. Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients.
Bleckman RF; Broekman KE; Roets E; Mohammadi M; Desar IME; Gelderblom H; Mathijssen RHJ; Steeghs N; de Graeff P; Reyners AKL
Drugs Aging; 2024 Feb; 41(2):165-176. PubMed ID: 38123766
[TBL] [Abstract][Full Text] [Related]
11. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
[TBL] [Abstract][Full Text] [Related]
12. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
[TBL] [Abstract][Full Text] [Related]
13. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
15. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
16. Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors.
Zhang Q; Xu J; Qian Y; Chen L; Li Q; Xu K; Chen M; Sun L; He Z; Yang L; Zhang D; Wang L; Sun X; Wang Y; Xu H; Xu Z
Mol Cancer Ther; 2018 Dec; 17(12):2780-2787. PubMed ID: 30282814
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
18. Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Chen H; Liu J; Zhou Y; Hou Y; Ma G; Cai W
Ther Drug Monit; 2019 Oct; 41(5):582-590. PubMed ID: 31045869
[TBL] [Abstract][Full Text] [Related]
19. Imatinib plasma levels in patients with gastrointestinal stromal tumour under routine clinical practice conditions.
Del Rosario García B; Morales Barrios JA; Jurado JC; Díaz RR; Viña Romero MM; Padrón IM; Nazco Casariego GJ; Nicolás FG
J Oncol Pharm Pract; 2023 Oct; 29(7):1613-1618. PubMed ID: 36482704
[TBL] [Abstract][Full Text] [Related]
20. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]